Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of Tadalafil in Men With Benign Prostatic Hyperplasia

Phase 3

Completed

Conditions: Benign Prostatic Hyperplasia (BPH)

Interventions: Drug: Tadalafil 5 mg
Drug: Placebo tablet
Drug: Tamsulosin
Drug: Placebo capsule

First Posted Date: 2009-09-02

Last Posted Date: 2012-03-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 511

Registration Number: NCT00970632

Locations: 🇵🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland

A Study of Olanzapine in Patients With Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Rapid-Acting Intramuscular Olanzapine
Drug: Placebo

First Posted Date: 2009-09-02

Last Posted Date: 2012-03-07

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 91

Registration Number: NCT00970281

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yamaguchi, Japan

A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder

Phase 3

Completed

Conditions: Attention Deficit Hyperactivity Disorder

Interventions: Drug: Atomoxetine

First Posted Date: 2009-09-01

Last Posted Date: 2012-12-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 211

Registration Number: NCT00969618

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan

A Study in Patients With Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: LY2439821
Drug: Placebo

First Posted Date: 2009-08-27

Last Posted Date: 2016-05-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 448

Registration Number: NCT00966875

Locations: 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan

A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder

Phase 2

Terminated

Conditions: Attention Deficit Hyperactivity Disorder

Interventions: Drug: Edivoxetine

First Posted Date: 2009-08-25

Last Posted Date: 2019-10-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 267

Registration Number: NCT00965419

Locations: 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kuei Shan Hsiang, Taiwan

A Study for Adult Patients With Fibromyalgia

Phase 4

Completed

Conditions: Fibromyalgia, Primary
Fibromyalgia, Secondary

Interventions: Drug: Duloxetine
Drug: Placebo

First Posted Date: 2009-08-25

Last Posted Date: 2011-11-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 308

Registration Number: NCT00965081

Locations: 🇲🇽
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Morelia, Mexico

Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder

Phase 3

Completed

Conditions: Attention Deficit Hyperactivity Disorder

Interventions: Drug: Atomoxetine
Drug: Placebo

First Posted Date: 2009-08-19

Last Posted Date: 2012-09-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 391

Registration Number: NCT00962104

Locations: 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan

A Duloxetine Dosing Strategy Study in Korean Patients With Major Depressive Disorder

Phase 4

Completed

Conditions: Major Depressive Disorder (MDD)

Interventions: Drug: Duloxetine hydrochloride

First Posted Date: 2009-08-18

Last Posted Date: 2014-12-31

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 249

Registration Number: NCT00960986

Locations: 🇰🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yangsan, Korea, Republic of

A Study in Relapse Prevention of Treatment-Resistant Depression

Phase 3

Completed

Conditions: Treatment Resistant Depression

Interventions: Drug: Olanzapine and Fluoxetine combination (OFC)
Drug: Fluoxetine

First Posted Date: 2009-08-13

Last Posted Date: 2014-04-01

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 892

Registration Number: NCT00958568

Locations: 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sisli, Turkey

Study of Participants With Advanced Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Advanced Non-Small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Carboplatin
Drug: Paclitaxel
Biological: Bevacizumab

First Posted Date: 2009-07-29

Last Posted Date: 2021-10-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 361

Registration Number: NCT00948675

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kennewick, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy